TNGX
Tango Therapeutics, Inc. · Healthcare · Market cap $4.5B
Insiders sold $2.2M net in the last 90 days ·2 sellers, 0 buyers· 4 of 4 sales under Rule 10b5-1 plans· latest Form 4 filed Oct 5, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$12.5M
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Latest filing
Oct 5, 2026
Crystal Adam
Tango Therapeutics, Inc. (TNGX) has 25 SEC Form 4 filings (47 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Oct 5, 2026.
Inside the rolling window, 5 insiders at Tango Therapeutics, Inc. reported no open-market purchases and 16 open-market sales totaling $12.5M. The most active filer is President, R&D Crystal Adam with 12 filings. Insiders have net sold $5.1M over the trailing 6 months. The most recent open-market filing is a sale of 27,000 shares by President, R&D Crystal Adam, dated Oct 1, 2026, worth $661K.
- Industry:Biotechnology
- CEO:Malte Peters
- Employees:137
- HQ:Boston, MA, US
- IPO:2020-09-03
| Source | |||||||
|---|---|---|---|---|---|---|---|
| President, R&D | Sale | 27,000 | $661K | Oct 5 | +16.9% | SEC ↗ | |
Newcomb JessicaFirst filing | Principal Accounting Officer | Sale | 8,200 | $199K | Sep 24 | +9.5% | SEC ↗ |
| President, R&D | Sale | 27,000 | $604K | Sep 3 | +18.5% | SEC ↗ | |
| President, R&D | Sale | 27,000 | $736K | Aug 5 | -6.3% | SEC ↗ | |
| President, R&D | Sale | 27,000 | $799K | Jul 2 | -8.4% | SEC ↗ | |
| President, R&D | Sale | 27,000 | $618K | Jun 3 | — | SEC ↗ | |
| President, R&D | Sale | 27,000 | $573K | May 5 | — | SEC ↗ | |
| President, R&D | Sale | 38,460 | $962K | Apr 16 | — | SEC ↗ | |
| President, R&D | Sale | 27,000 | $572K | Apr 2 | — | SEC ↗ | |
| President, R&D | Sale | 12,000 | $241K | Mar 27 | — | SEC ↗ | |
| President, R&D | Sale | 20,251 | $304K | Mar 9 | — | SEC ↗ | |
| President, R&D | Sale | 54,345 | $694K | Feb 27 | — | SEC ↗ | |
Weber BarbaraFirst filing | Director, Executive Chair | Sale | 30,519 | $374K | Feb 4 | — | SEC ↗ |
Beckman DaniellaFirst filing | Chief Financial Officer | Sale | 10,317 | $127K | Feb 4 | — | SEC ↗ |
Crystal AdamFirst filing | President, R&D | Sale | 18,452 | $226K | Feb 4 | — | SEC ↗ |
Third Rock Ventures IV, L.P.First filing | 10% Owner | Sale | 477,401 | $4.8M | Oct 27 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does TNGX have?
Tango Therapeutics, Inc. (TNGX) has 25 SEC Form 4 filings (47 transaction rows) in the rolling 365-day window, disclosed by 5 distinct insiders. Most recent filing: Oct 5, 2026.
When was the most recent SEC Form 4 filing for TNGX?
The most recent Form 4 filing for TNGX on Tracefour is dated Oct 5, 2026.
Who is the most active insider at TNGX?
The most active SEC Form 4 filer at TNGX in the rolling window is President, R&D Crystal Adam, with 12 filings.
What is the net insider flow at TNGX over the last 6 months?
Over the trailing 180 days, insiders at TNGX have net sold $5.1M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at TNGX in the current window?
Inside the rolling window, insiders at TNGX bought $0 and sold $12.5M based on SEC Form 4 filings.
Can I get alerts for TNGX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Tango Therapeutics, Inc. (TNGX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Tango Therapeutics, Inc. is in the Healthcare sector.